Compare GLDD & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | AKBA |
|---|---|---|
| Founded | 1890 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 729.1M |
| IPO Year | 2007 | 2014 |
| Metric | GLDD | AKBA |
|---|---|---|
| Price | $16.96 | $1.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.00 | $5.75 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 05-26-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.57 | ★ 93.94 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $3.79 | $1.84 |
| Revenue Next Year | $9.01 | N/A |
| P/E Ratio | $15.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.51 | $1.14 |
| 52 Week High | $16.99 | $4.08 |
| Indicator | GLDD | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 56.36 |
| Support Level | $14.60 | $1.16 |
| Resistance Level | $16.99 | $1.52 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 80.00 | 67.89 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.